芳香化酶抑制剂治疗晚期复发性子宫内膜癌初探

目的 初步探讨芳香化酶抑制剂-兰他隆治疗复发性子宫内膜癌的临床效果。方法 对3例手术后复发、化疗及放疗后病情未控的子宫内膜癌患者，应用兰他隆250mg，肌肉注射，每2周1次，8周为一疗程，治疗期间每周化验外周血象、肝肾功能，疗程结束后2周评判疗效。结果 1例病情完全缓解，1例病情稳定，1例病情进展。3例患者均未出现与用药有关的毒副作用。结论 芳香化酶抑制剂兰他隆治疗复发性子宫内膜癌有一定的临床效果，且无明显毒副作用。

Clinical analysis of relapsed endometrial carcinoma treated with aromatase inhibitor lantaron

Objective To evaluate the outcome of relapsed endometrial carcinoma treated with aromatase inhibitor Lantaron. Methods Three women with postoperative relapsed endometrial carcinoma, who were with uncontrolled disease after chemotherapy or/and radiotherapy, treated with Lantaron at 250 mg/2 weeks, 8 weeks/course, muscular injection. Peripheral blood cells were counted and the function of liver and kidney were checked every week during the treatment. The clinical outcome was evaluated at 2 weeks after the course finished. Results One of the 3 cases was complete response, one was stable disease and the other one was disease progression. No obvious toxicity was found in this study. Conclusions Aromatase inhibitor, Lantaron can be a selvage drug to treat refractory endometrial carcinoma, without severe side effect.